Healthcare Global Enterprises Ltd

Total operating expenditure for the period under review was Rs 559.16 crore, up 16.6% YoY. The company recorded an exceptional charge of Rs 31.91 crore in the March 2026 quarter. HealthCare Global stated that during the quarter and year ended 31 March 2026, the management committed to a plan to divest the company's entire equity interest in BACC Healthcare (BACC), a wholly owned subsidiary engaged in the management of infertility treatment hospitals. Pursuant to the investor outreach process, non-binding offers were received from potential investors. Accordingly, the assets and liabilities of BACC have been classified as a disposal group held for sale as at 31 March 2026. Along with the classification as held for sale, the carrying amount of goodwill allocated to the cash-generating unjt (i.e., BACC) was assessed for impainnent and an impairment loss of Rs 31.91 crore has been recognised as an exceptional item for the quarter and year ended 31 March 2026 based on the net fair value of the consideration receivable. Accordingly, profit before tax in Q4 FY26 stood at Rs 1.25 crore in Q4 FY26, down by 90.8% from Rs 13.62 crore in Q4 FY25. For FY26, the company has recorded consolidated net profit and revenue from operations of Rs 13.76 crore (down 69% YoY) and Rs 2,538.43 crore (up 14.4% YoY), respectively. HealthCare Global Enterprises (HCG) is India's largest dedicated cancer hospital network, operating 25 hospitals across India and Africa. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under 'Milann', HCG operates fertility centers as well. The scrip rose 1.58% to currently trade at Rs 656.90 on the BSE. Powered by Capital Market - Live

Net profit of Healthcare Global Enterprises declined 70.52% to Rs 2.17 crore in the quarter ended March 2026 as against Rs 7.36 crore during the previous quarter ended March 2025. Sales rose 11.46% to Rs 650.29 crore in the quarter ended March 2026 as against Rs 583.43 crore during the previous quarter ended March 2025. For the full year,net profit declined 69.02% to Rs 13.76 crore in the year ended March 2026 as against Rs 44.41 crore during the previous year ended March 2025. Sales rose 14.44% to Rs 2538.43 crore in the year ended March 2026 as against Rs 2218.14 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales650.29583.43 11 2538.432218.14 14 OPM %19.2318.11 -18.3517.46 - PBDT95.9771.69 34 315.67268.30 18 PBT33.1613.62 143 71.5056.96 26 NP2.177.36 -71 13.7644.41 -69 Powered by Capital Market - Live

Healthcare Global Enterprises has today launched its new comprehensive cancer hospital in Hebbal with up to 132 beds, strengthening access to advanced oncology care in North Bengaluru (HCG Cancer Hospital, Hebbal). The new facility marks a major advancement in the region's oncology landscape, bringing together clinical excellence, compassionate care and advanced technology to make world-class cancer treatment more accessible to people across Karnataka. Marking a significant milestone in precision oncology, the new facility introduces Karnataka's first Elekta Unity MR-Linac, one of the world's most advanced precision radiation therapy platforms. The technology combines high-quality MRI imaging with a linear accelerator to enable highly precise, adaptive cancer treatment. Designed as a full-spectrum oncology centre, the hospital brings together diagnosis, treatment, recovery support, and patient-centric care under one roof, making world-class cancer care more accessible to patients across North Bengaluru.

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 19 May 2026.

The board of Healthcare Global Enterprises at its meeting held on 24 February 2025 has approved the terms of rights issue: Instrument: Fully paid-up equity shares of face value of Rs 10 each. Total number of Rights Equity Shares and Rights Issue size: 82,94,566 Rights Equity Shares each for an amount aggregating to Rs 424.68 crore (assuming full subscription and payment of call monies). Rights Issue Price: Rs 512 (Rupees Five Hundred and Twelve only) per Rights Equity Share (including a premium of Rs 502 (Rupees Five Hundred and Two only) per Rights Equity Share) Concept of Rights Entitlement: The shareholders holding equity shares of the Company as on the Record date ('eligible equity shareholders') will be entitled to Rights Entitlement ('REs'). REs shall be credited prior to the issue opening date, in the respective demat account of the eligible equity shareholders ('RE Holders') under the ISIN: INE075I20017. The Company has made necessary arrangements with NSDL and CDSL for credit of REs in the respective demat account of the eligible equity shareholders. RE holders can apply for Rights Issue or renounce the REs in full or in part. Record date: 02 March 2026 Issue opening date: 11 March 2026 Issue closing date: 25 March 2026 Date of listing of rights issue: 01 April 2026 Rights Entitlement Ratio: The Rights Equity Shares are being offered on a rights basis to Eligible Equity Shareholders in the ratio of 1 (One) Rights Equity Shares for every 17 (Seventeen) fully paid-up Equity Shares held on the Record Date. Powered by Capital Market - Live

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 24 February 2026.Powered by Capital Market - Live

These funds will be raised by offering new shares to the company's existing eligible equity shareholders. The total number of securities to be issued will be finalized by the board's rights issue committee at a later stage. The company further said that the record date, which determines shareholder eligibility, will be decided and notified in a subsequent filing. HealthCare Global Enterprises is one of India's largest oncology hospital chains. HCG operates 25 medical care centers across 19 cities with best-in-class infrastructure including 2,500 beds, nearly 100 operating theaters and 40 linear accelerator machines (LINACs). HealthCare Global Enterprises (HCG) is India's largest dedicated cancer hospital network, operating 25 hospitals across India and Africa. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under 'Milann', HCG operates fertility centers as well. The company had reported a net loss of Rs 9.43 crore in the quarter ended December 2025 as against net profit of Rs 6.98 crore during the previous quarter ended December 2024. Sales rose 13.21% to Rs 631.18 crore in Q3 FY26 over Q3 FY25. The scrip was down 0.08% to currently trade at Rs 578 on the BSE. Powered by Capital Market - Live

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 17 February 2026.Powered by Capital Market - Live

Net loss of Healthcare Global Enterprises reported to Rs 9.43 crore in the quarter ended December 2025 as against net profit of Rs 6.98 crore during the previous quarter ended December 2024. Sales rose 13.21% to Rs 631.18 crore in the quarter ended December 2025 as against Rs 557.55 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales631.18557.55 13 OPM %17.3615.85 - PBDT67.2553.22 26 PBT6.60-3.30 LP NP-9.436.98 PL Powered by Capital Market - Live

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live